Outset Medical, Inc.
NASDAQ:OMMedical - Devices
+$0.73 today
- Market cap
- $57.31M
- Beta
- 1.94
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$4.07
Volume 0.05M
Average 0.16M
OM Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Outset Medical, Inc.NASDAQ: OM
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $382K fell 70.5% year over year, behind the -56.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 56.6% from the prior quarter. Over 3 fiscal years it compounded at -11.6% a year.
Context
- Depreciation & amortization amounted to 3.6% of revenue in FY2025, down 1.4 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -70.5% toward the trailing-twelve-month pace of -56.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 4.34M USD
- Year-over-year change
- -24.2%
- 4-year CAGR
- -4.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.34M | -24.2% |
| FY2024 | 2024-12-31 | 5.73M | -1.4% |
| FY2023 | 2023-12-31 | 5.81M | -7.5% |
| FY2022 | 2022-12-31 | 6.28M | +21.7% |
| FY2021 | 2021-12-31 | 5.16M | — |
Depreciation & Amortization vs competitors
How OM compares with its peers on the latest reported figures
- OM's LTM Mar 2026 depreciation & amortization of $2.74M is the 8th highest of the 10 companies compared; the peer median is $7.54M.
- Its year-over-year change of -56.6% is the lowest of 10, against a peer median of +32.3%.
- Depreciation & amortization amounts to 2.3% of revenue for OM, versus a peer median of 10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $29.62M | +15.3% | +22.3% | 10.3% | |
| LTM Mar 2026 | $21.08M | +133.7% | +51.8% | 14.5% | |
| LTM Mar 2026 | $20.37M | -2.6% | -4.2% | 5.8% | |
| LTM Dec 2025 | $11.7M | -0.3% | +0.5% | 89.8% | |
| LTM Mar 2026 | $7.54M | -16.0% | -1.1% | 3350.2% | |
| LTM Mar 2026 | $3.67M | +210.5% | — | 6.8% | |
| LTM Mar 2026 | $3.65M | +35.4% | +111.4% | 589.8% | |
| LTM Mar 2026 | $2.74M | -56.6% | -11.6% | 2.3% | |
| LTM Mar 2026 | $1.59M | +32.3% | +10.5% | 3.6% | |
| LTM Mar 2026 | $672K | +1192.3% | +38.7% | 7.0% | |
| Peer median (excluding OM) | $7.54M | +32.3% | +16.4% | 10.3% | |
Competitors are the stored peer set for OM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 102.6M | 115.38M | 130.38M | 113.69M | 119.48M |
| Cost of Revenue | 94.99M | 97.54M | 101.38M | 75.13M | 72.72M |
| Gross Profit | 7.61M | 17.83M | 29M | 38.56M | 46.75M |
| Gross Margin | 7.4% | 15.5% | 22.2% | 33.9% | 39.1% |
| Research & Development | 36.74M | 48.86M | 57.31M | 38.4M | 21.24M |
| Selling, General & Admin | 101.39M | 130M | 141.46M | 113.54M | 92.23M |
| Operating Expenses | 138.13M | 178.85M | 198.77M | 151.94M | 113.46M |
| Depreciation & Amortization | 5.16M | 6.28M | 5.81M | 5.73M | 4.34M |
| EBITDA | (124.86M) | (152.81M) | (153.79M) | (97.89M) | (62.37M) |
| EBITDA Margin | -121.7% | -132.4% | -118.0% | -86.1% | -52.2% |
| Operating Income | (130.52M) | (161.02M) | (169.77M) | (113.38M) | (66.71M) |
| Operating Margin | -127.2% | -139.6% | -130.2% | -99.7% | -55.8% |
| Interest Income | 498K | 3.29M | 10.17M | 9.76M | 7.41M |
| Interest Expense | 1.72M | 3.57M | 12.68M | 23.87M | 13.95M |
| Other Income / Expenses | (1.22M) | (1.64M) | (2.5M) | (14.11M) | (14.22M) |
| Income Before Tax | (131.74M) | (162.66M) | (172.27M) | (127.49M) | (80.94M) |
| Pre-Tax Margin | -128.4% | -141.0% | -132.1% | -112.1% | -67.7% |
| Income Tax Expense | 199K | 295K | 523K | 491K | 718K |
| Net Income | (131.94M) | (162.96M) | (172.8M) | (127.98M) | (81.65M) |
| Net Margin | -128.6% | -141.2% | -132.5% | -112.6% | -68.3% |
| EPS (Basic) | (43.41) | (50.75) | (52.27) | (36.95) | (5.37) |
| EPS (Diluted) | (43.41) | (50.75) | (52.27) | (36.95) | (5.37) |
| Weighted Avg Shares | 3.04M | 3.21M | 3.31M | 3.46M | 15.21M |
| Weighted Avg Shares (Diluted) | 3.04M | 3.21M | 3.31M | 3.46M | 15.21M |
Outset Medical, Inc.
NASDAQ:OM
Intrinsic Alpha fair value
Locked
Current Price
$3.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.